Grifols stock trades below recent highs as valuation focus grows
Published on 09/11/2026 at 20:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols, S.A. (ISIN ES0171996087) stock finished the September 10, 2026 session on the Nasdaq at USD 8.34, a 3.6 percent decline from the prior close that left the shares clearly below their recent highs per Nasdaq data cited by Yahoo Finance.
Recent price move and trading range
According to Ad-hoc-news.de on September 11, 2026, Grifols stock closed at USD 8.34 on the Nasdaq on September 10, 2026, down 3.6 percent from the previous close after opening near USD 8.60 and trading within an intraday range that stayed between the day’s high and low.
The same overview notes that the 52-week range for Grifols American depositary shares in US trading ran roughly between USD 6.00 and USD 10.50 as of September 10, 2026, placing the latest close in the lower half of that band and indicating that the stock is trading at a noticeable distance from its recent high.
Valuation metrics and peer comparison
As Zacks reported on September 11, 2026, Grifols stock currently carries a forward price-earnings ratio of 7.03, compared with a much higher forward P/E of 20.54 for Sandoz Group AG Sponsored ADR, highlighting a wide valuation gap between the two healthcare names.
In the same comparison, Zacks points out that Grifols has a PEG ratio of 0.28, suggesting that, based on its earnings growth outlook, the shares trade at a discount relative to that growth profile when compared with Sandoz’s richer valuation.
Earnings outlook and investor focus
The valuation discussion from Zacks emphasizes that Grifols has seen a stronger improvement in its earnings outlook than Sandoz recently, and on that basis the research house assigns Grifols a Zacks Rank of 2 (Buy) versus a Rank of 3 (Hold) for Sandoz.
For investors, that combination of a relatively low forward P/E of 7.03 and a PEG ratio of 0.28 as of September 11, 2026, together with the Rank 2 rating, positions Grifols stock as a value-oriented play in the plasma-derived medicines and healthcare space, especially given that the shares closed in the lower half of their 52-week range just one trading day earlier.
Trading venue and market context
Grifols American depositary shares trade on the Nasdaq under the ticker GRFS, while the company’s primary listing in Europe is on BME (Bolsa de Madrid) under the ticker GRF, where the stock most recently recorded a closing price around EUR 9.996 with daily moves in early September 2026 according to data compiled by Zonebourse.
The reference for US investors remains the Nasdaq quote in USD, where the September 10, 2026 close at USD 8.34, combined with the USD 6.00 to USD 10.50 52-week span cited by Ad-hoc-news.de, indicates that the shares are trading nearer to their recent lows than their highs as of mid-September 2026.
Stock level and investor takeaway
At the close of September 10, 2026, Grifols stock stood at USD 8.34 on the Nasdaq in USD, within a 52-week range running from about USD 6.00 to USD 10.50 and reflecting a 3.6 percent daily decline, a pattern that keeps valuation metrics such as the 7.03 forward P/E and 0.28 PEG ratio in sharp focus for investors assessing the risk-reward profile.
Grifols stock - key data
- Company: Grifols, S.A.
- ISIN: ES0171996087
- Ticker: GRFS
- Trading venue: Nasdaq
- Price (as of September 10, 2026): 8.34 USD
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Ibex 35
